King Fahad Armed Forces Hospital Begins Trial of New Bioadaptive Angioplasty Procedure for Heart Disease Treatment

Unique device opens coronary arteries and restores the artery to naturally pulse for increased blood flow and heart recovery

KSA, April 29, 2024 – King Fahad Armed Forces Hospital is the first in the Kingdom of Saudi Arabia to begin clinical research and offer a new type of angioplasty procedure with the DynamX® bioadaptor, a novel coronary implant designed to restore vessel function in patients with coronary artery disease (CAD). The bioadaptor is an innovative implant that, after the period of healing, unlocks and allows the artery to pulse and function more naturally in response to a patient’s exertion and the heart’s changing needs. More normal artery motion and expansion help the artery restore its healthy function and reduce the risks of secondary adverse events such as heart attacks or repeat procedures. The new procedure is being offered to patients under the leadership of Dr. Mirvat Alasnag, head of Catheterization Lab, Dr. Khalid Al Shaibi, director of Cardiac Center, Dr. Waqar Ahmed, interventional cardiologist, Dr. Salem Assiri, interventional cardiologist, and Dr. Sultan Alotaibi, interventional cardiologist.

“We are pleased to offer the bioadaptive angioplasty at King Fahd Armed Forces Hospital to patients suffering from CAD, and especially for those who are younger and seek to reclaim an active lifestyle,” said Mirvat Alasnag, M.D., head of the Catheterization Laboratory at the King Fahd Armed Forces Hospital in Jeddah, Saudi Arabia.

King Fahd Armed Forces Hospital, one of the premier hospitals and clinical research centers, is also participating in the global BIO-RESTORE post-market registry for the bioadaptor to generate diverse, in-market experience, specifically in Saudi patients.

The DynamX bioadaptor is a metallic coronary device that is implanted via a minimally invasive angioplasty procedure. It is designed to provide dynamic vessel support and establish adaptive hemodynamic modulation of the artery, enabling vessel function and motion and increased blood flow. It consists of three thin metal alloy helical strands held together temporarily by a bioabsorbable coating to provide strength when opening artery blockage. Unlike traditional stents, after the period of healing and coating resorption in the first six months, the bioadaptor unlocks and the helical strands separate, thereby restoring hemodynamic modulation of the vessel and establishing more natural and dynamic support of artery motion and function.

The bioadaptor can also expand slowly over time along with the artery in order to maintain good blood flow.1 Recent findings also show stabilization and even shrinking of plaque volume in arteries treated with the bioadaptor.2

About Coronary Artery Disease

Coronary artery disease (CAD) is the most common form of heart disease in the world3 and a leading cause of death.4 It is caused by a buildup of fatty deposits and other substances in the walls of the arteries that supply blood to the heart and other parts of the body. Over time, the buildup causes the inside of the arteries to stiffen and narrow, and lose their natural functions, which can partially or totally block the flow of blood and nutrients to the heart. Chest pain is the most common symptom of CAD. For many people, a heart attack is the first sign that they have CAD.

About Elixir Medical

Elixir Medical Corporation, a privately-held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheral artery disease. The company’s technologies have multiple applications across the cardiovascular and peripheral space designed to deliver improved clinical outcomes for millions of patients. Visit us at and on LinkedIn.

About King Fahad Armed Forces Hospital


MEDIA CONTACT: Lisa George. Iris PR, Dubai, UAE. Tel: +9714 434 1207. Email:

  1. Verheye, S. et al. Twelve-month clinical and imaging outcomes of the uncaging coronary DynamX bioadaptor system. EuroIntervention 2020;16:e974-e981.
  2. Saito, S, et al. First randomised controlled trial comparing the sirolimus-eluting bioadaptor with the zotarolimus-eluting drug-eluting stent in patients with de novo coronary arty lesions: 12-month clinical and imaging data from the multi-centre, international, BIOADAPTOR-RCT. The Lancet Nov 2023; 1-13.
  3. Coronary artery disease. Centers for Disease Control and Prevention. Accessed August 21, 2021.
  4. World Health Organization Web site. Cardiovascular diseases (CVDs) [Internet]. 2017 [cited 2017 Dec 19]. Available from: